Benzinga · Aug 10, 2026
Evercore ISI Group Maintains Outperform on Arvinas, Lowers Price Target to $14
Evercore ISI Group analyst Jonathan Miller maintains Arvinas (NASDAQ:ARVN) with a Outperform and lowers the price target from $19 to $14.
AR
NASDAQ · ARVN
Arvinas, Inc.
Healthcare · Biotechnology
$9.01
Up+$0.14 (+1.58%)
Updated Aug 14, 2026, 12:30 PM
SID Score
4.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 974.25M
- P/E ratio
- -10.66
- Dividend yield
- 0.00%
- 52-week range
- $6.74 – $14.51
- Volume
- 939.14K
- Avg. volume
- 876.56K
Price performance
ARVN price history
1M range · 21 trading sessions · Daily adjusted prices
ARVN closed at $9.01 after 21 trading sessions, up 12.20% for the selected period.
- Last close
- $9.01
- Period change
- +12.20%
- Period low
- $8.01
- Period high
- $9.01
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 13, 2026 | $8.91 | $9.09 | $8.855 | $9.01 | 939.14K |
| Aug 12, 2026 | $8.99 | $8.99 | $8.71 | $8.87 | 524.46K |
| Aug 11, 2026 | $8.99 | $9.115 | $8.86 | $8.99 | 572.1K |
| Aug 10, 2026 | $8.70 | $9.02 | $8.5901 | $8.99 | 671.77K |
| Aug 7, 2026 | $8.81 | $8.98 | $8.64 | $8.75 | 1.22M |
| Aug 6, 2026 | $8.40 | $8.7163 | $8.37 | $8.68 | 2.58M |
| Aug 5, 2026 | $8.82 | $8.91 | $8.21 | $8.40 | 1.57M |
| Aug 4, 2026 | $8.33 | $9.65 | $8.33 | $9.00 | 3.03M |
| Aug 3, 2026 | $8.10 | $8.17 | $7.92 | $8.06 | 716.84K |
| Jul 31, 2026 | $8.24 | $8.24 | $7.895 | $8.03 | 687.9K |
| Jul 30, 2026 | $8.11 | $8.305 | $8.10 | $8.30 | 550.06K |
| Jul 29, 2026 | $8.18 | $8.34 | $8.09 | $8.22 | 740.47K |
| Jul 28, 2026 | $8.255 | $8.32 | $8.015 | $8.20 | 551.92K |
| Jul 27, 2026 | $8.13 | $8.37 | $8.12 | $8.22 | 475.56K |
| Jul 24, 2026 | $8.11 | $8.16 | $7.95 | $8.03 | 385.67K |
| Jul 23, 2026 | $8.10 | $8.31 | $8.04 | $8.12 | 704.98K |
| Jul 22, 2026 | $8.21 | $8.40 | $8.15 | $8.26 | 642.47K |
| Jul 21, 2026 | $8.02 | $8.29 | $7.96 | $8.26 | 625.54K |
| Jul 20, 2026 | $8.02 | $8.21 | $7.97 | $8.02 | 555.53K |
| Jul 17, 2026 | $7.95 | $8.175 | $7.90 | $8.01 | 519.86K |
| Jul 16, 2026 | $8.30 | $8.30 | $7.98 | $8.03 | 634.53K |
Latest ARVN news
The latest Smart Investors Daily articles mentioning ARVN.
Stock researchCompany · Overview
ARVN research
Overview
Company profile and research snapshot.
Company profile
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $13.20
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 10, 2026 | Citigroup | Buy | — |
| Aug 10, 2026 | Evercore ISI Group | Outperform | — |
| Aug 5, 2026 | Wedbush | Neutral | — |
| Aug 5, 2026 | Wells Fargo | Equal-Weight | — |
| Aug 4, 2026 | BTIG | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 10, 2026
Citigroup Maintains Buy on Arvinas, Lowers Price Target to $21
Citigroup analyst Yigal Nochomovitz maintains Arvinas (NASDAQ:ARVN) with a Buy and lowers the price target from $24 to $21.
SeekingAlpha · Aug 5, 2026
Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead
Rigel Pharmaceuticals in-licensed Veppanu, a drug for the treatment of certain breast cancer patients, targeting a $1B market. Read why RIGL stock is a Buy.
Benzinga · Aug 5, 2026
Wells Fargo Downgrades Arvinas to Equal-Weight, Lowers Price Target to $11
Wells Fargo analyst Derek Archila downgrades Arvinas (NASDAQ:ARVN) from Overweight to Equal-Weight and lowers the price target from $15 to $11.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
